Kim P. C. Kuypers

List of Publications by Year
in descending order

100	3,479	109264 35	182361 51
papers	citations	h-index	g-index

111	111	111	2703
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Psychotomimetic symptoms after a moderate dose of a synthetic cannabinoid (JWH-018): implications for psychosis. Psychopharmacology, 2022, 239, 1251-1261.	1.5	12
2	A systematic review of (pre)clinical studies on the therapeutic potential and safety profile of kratom in humans. Human Psychopharmacology, 2022, 37, e2805.	0.7	19
3	Self-Rated Recovery and Mood Before and After Resistance Training and Muscle Microcurrent Application. Frontiers in Psychology, 2022, 13, 836695.	1.1	2
4	A Comparison of Acute Neurocognitive and Psychotomimetic Effects of a Synthetic Cannabinoid and Natural Cannabis at Psychotropic Dose Equivalence. Frontiers in Psychiatry, 2022, 13, .	1.3	3
5	Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls. Scientific Reports, 2022, 12, .	1.6	13
6	Self-Medication with Ganoderma lucidum (â€œReishiâ€) to Combat Parkinson's Disease Symptoms: A Single Case Study. Journal of Medicinal Food, 2021, 24, 766-773.	0.8	3
7	Low Doses of LSD Acutely Increase BDNF Blood Plasma Levels in Healthy Volunteers. ACS Pharmacology and Translational Science, 2021, 4, 461-466.	2.5	71
8	Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide Microdoses in Healthy Participants. Clinical Pharmacology and Therapeutics, 2021, 109, 658-666.	2.3	26
9	A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers. Journal of Psychopharmacology, 2021, 35, 398-405.	2.0	47
10	Microdosing Psychedelics as a Promising New Pharmacotherapeutic. , 2021, , 257-274.		1
11	Exploring the use of Kratom (Mitragyna speciosa) via the YouTube data tool: A novel netnographic analysis. Emerging Trends in Drugs, Addictions, and Health, 2021, 1, 100007.	0.5	10
12	Intoxication by a synthetic cannabinoid (JWH-018) causes cognitive and psychomotor impairment in recreational cannabis users. Pharmacology Biochemistry and Behavior, 2021, 202, 173118.	1.3	11
13	A placebo-controlled study of the effects of ayahuasca, set and setting on mental health of participants in ayahuasca group retreats. Psychopharmacology, 2021, 238, 1899-1910.	1.5	51
14	Spontaneous and deliberate creative cognition during and after psilocybin exposure. Translational Psychiatry, 2021, 11, 209.	2.4	46
15	Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics. Frontiers in Psychiatry, 2021, 12, 724606.	1.3	83
16	Persisting Effects of Ayahuasca on Empathy, Creative Thinking, Decentering, Personality, and Well-Being. Frontiers in Pharmacology, 2021, 12, 721537.	1.6	24
17	The effect of intranasally administered oxytocin on observed social behavior in social anxiety disorder. European Neuropsychopharmacology, 2021, 53, 25-33.	0.3	9
18	Acute and Long-Term Effects of Ayahuasca on (Higher-Order) Cognitive Processes. , 2021, , 117-136.		1

#	Article	IF	Citations
19	Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers. Scientific Reports, 2021, 11, 22479.	1.6	25
20	Alcohol- and drug-related public violence in Europe. European Journal of Criminology, 2020, 17, 806-825.	1.5	10
21	Intoxicated aggression: Do alcohol and stimulants cause dose-related aggression? A review. European Neuropsychopharmacology, 2020, 30, 114-147.	0.3	30
22	Mood and cognition after administration of low LSD doses in healthy volunteers: A placebo controlled dose-effect finding study. European Neuropsychopharmacology, 2020, 41, 81-91.	0.3	62
23	The therapeutic potential of microdosing psychedelics in depression. Therapeutic Advances in Psychopharmacology, 2020, 10, 204512532095056.	1.2	42
24	Me, myself, bye: regional alterations in glutamate and the experience of ego dissolution with psilocybin. Neuropsychopharmacology, 2020, 45, 2003-2011.	2.8	127
25	Depression, Mindfulness, and Psilocybin: Possible Complementary Effects of Mindfulness Meditation and Psilocybin in the Treatment of Depression. A Review. Frontiers in Psychiatry, 2020, 11, 224.	1.3	37
26	Microdosing psychedelics: More questions than answers? An overview and suggestions for future research. Journal of Psychopharmacology, 2019, 33, 1039-1057.	2.0	121
27	Cocaine enhances figural, but impairs verbal â€˜flexibleâ€™ divergent thinking. European Neuropsychopharmacology, 2019, 29, 813-824.	0.3	10
28	Self-Rated Effectiveness of Microdosing With Psychedelics for Mental and Physical Health Problems Among Microdosers. Frontiers in Psychiatry, 2019, 10, 672.	1.3	36
29	Motives for Classical and Novel Psychoactive Substances Use in Psychedelic Polydrug Users. Contemporary Drug Problems, 2019, 46, 304-320.	0.7	21
30	A First-in-Man Study with 4-Fluoroamphetamine Demonstrates it Produces a Mild Psychedelic State. Journal of Psychoactive Drugs, 2019, 51, 225-235.	1.0	5
31	Motives and Side-Effects of Microdosing With Psychedelics Among Users. International Journal of Neuropsychopharmacology, 2019, 22, 426-434.	1.0	77
32	Neurocognition and Subjective Experience Following Acute Doses of the Synthetic Cannabinoid JWH-018: Responders Versus Nonresponders. Cannabis and Cannabinoid Research, 2019, 4, 51-61.	1.5	18
33	Pharmacokinetic properties of 4â€fluoroamphetamine in serum and oral fluid after oral ingestion. Drug Testing and Analysis, 2019, 11, 1028-1034.	1.6	8
34	A single inhalation of vapor from dried toad secretion containing 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting is related to sustained enhancement of satisfaction with life, mindfulness-related capacities, and a decrement of psychopathological symptoms. Psychopharmacology, 2019, 236, 2653-2666.	1.5	99
35	Sub-Acute Effects of Psilocybin on Empathy, Creative Thinking, and Subjective Well-Being. Journal of Psychoactive Drugs, 2019, 51, 123-134.	1.0	91
36	Psychedelic medicine: The biology underlying the persisting psychedelic effects. Medical Hypotheses, 2019, 125, 21-24.	0.8	25

#	Article	IF	Citations
37	Increased Temporal Discounting in Social Anxiety Disorder Normalizes after Oxytocin Treatment. Psychotherapy and Psychosomatics, 2019, 88, 55-57.	4.0	10
38	Mephedrone and Alcohol Interactions in Humans. Frontiers in Pharmacology, 2019, 10, 1588.	1.6	21
39	Out of the box: A psychedelic model to study the creative mind. Medical Hypotheses, 2018, 115, 13-16.	0.8	9
40	Depressive mood ratings are reduced by MDMA in female polydrug ecstasy users homozygous for the l-allele of the serotonin transporter. Scientific Reports, 2018, 8, 1061.	1.6	13
41	MDMA-induced indifference to negative sounds is mediated by the 5-HT2A receptor. Psychopharmacology, 2018, 235, 481-490.	1.5	17
42	Peripheral endocannabinoid concentrations are not associated with verbal memory impairment during MDMA intoxication. Psychopharmacology, 2018, 235, 709-717.	1.5	6
43	Neurocognition and subjective experience following acute doses of the synthetic cannabinoid JWHâ€018: a phase 1, placeboâ€controlled, pilot study. British Journal of Pharmacology, 2018, 175, 18-28.	2.7	34
44	Independent elevation of peripheral oxytocin concentrations and reduction in cognitive empathy during 4â€fluoroamphetamine intoxication. Human Psychopharmacology, 2018, 33, e2680.	0.7	5
45	Drug liking and wanting, not impulsive action or reflection is increased by 4-fluoroamphetamine. Psychopharmacology, 2018, 235, 2349-2356.	1.5	8
46	Mental health of a self-selected sample of psychedelic users and self-medication practices with psychedelics. Journal of Psychedelic Studies, 2018, 2, 45-52.	0.5	15
47	A single dose of cocaine enhances prospective memory performance. Journal of Psychopharmacology, 2018, 32, 883-892.	2.0	4
48	Safety Profile and Neurocognitive Function Following Acute 4-Fluoroamphetamine (4-FA) Administration in Humans. Frontiers in Pharmacology, 2018, 9, 713.	1.6	14
49	Sub-acute and long-term effects of ayahuasca on affect and cognitive thinking style and their association with ego dissolution. Psychopharmacology, 2018, 235, 2979-2989.	1.5	134
50	Brain reactivity to alcohol and cannabis marketing during sobriety and intoxication. Addiction Biology, 2017, 22, 823-832.	1.4	22
51	Multifaceted empathy of healthy volunteers after single doses of MDMA: A pooled sample of placebo-controlled studies. Journal of Psychopharmacology, 2017, 31, 589-598.	2.0	70
52	A pooled analysis of on-the-road highway driving studies in actual traffic measuring standard deviation of lateral position (i.e., â€œweavingâ€) while driving at a blood alcohol concentration of 0.5Âg/L. Psychopharmacology, 2017, 234, 837-844.	1.5	41
53	MDMA-Induced Dissociative State not Mediated by the 5-HT2A Receptor. Frontiers in Pharmacology, 2017, 8, 455.	1.6	13
54	Emotional Empathic Responses to Dynamic Negative Affective Stimuli Is Gender-Dependent. Frontiers in Psychology, 2017, 8, 1491.	1.1	9

#	Article	IF	Citations
55	Interactions between mephedrone and alcohol in humans: Cardiovascular and subjective effects. European Psychiatry, 2016, 33, S115-S115.	0.1	4
56	Neurocognitive performance following acute mephedrone administration, with and without alcohol. Journal of Psychopharmacology, 2016, 30, 1305-1312.	2.0	22
57	Subjective aggression during alcohol and cannabis intoxication before and after aggression exposure. Psychopharmacology, 2016, 233, 3331-3340.	1.5	37
58	Ayahuasca enhances creative divergent thinking while decreasing conventional convergent thinking. Psychopharmacology, 2016, 233, 3395-3403.	1.5	125
59	Ayahuasca enhances creative divergent thinking. European Neuropsychopharmacology, 2016, 26, S705-S706.	0.3	1
60	Cannabis and tolerance: acute drug impairment as a function of cannabis use history. Scientific Reports, 2016, 6, 26843.	1.6	50
61	Cannabis and cocaine decrease cognitive impulse control and functional corticostriatal connectivity in drug users with low activity DBH genotypes. Brain Imaging and Behavior, 2016, 10, 1254-1263.	1.1	52
62	Verbal Memory Impairment in Polydrug Ecstasy Users: A Clinical Perspective. PLoS ONE, 2016, 11, e0149438.	1.1	19
63	MDMA, cannabis, and cocaine produce acute dissociative symptoms. Psychiatry Research, 2015, 228, 907-912.	1.7	28
64	Rivastigmine but not vardenafil reverses cannabis-induced impairment of verbal memory in healthy humans. Psychopharmacology, 2015, 232, 343-353.	1.5	26
65	Psychedelic symptoms of cannabis and cocaine use as a function of trait impulsivity. Journal of Psychopharmacology, 2015, 29, 324-334.	2.0	19
66	Emotion recognition during cocaine intoxication. European Neuropsychopharmacology, 2015, 25, 1914-1921.	0.3	15
67	Changes in serotonin transporter (5-HTT) gene expression in peripheral blood cells after MDMA intake. Psychopharmacology, 2015, 232, 1921-1929.	1.5	11
68	No Evidence that MDMA-Induced Enhancement of Emotional Empathy Is Related to Peripheral Oxytocin Levels or 5-HT1a Receptor Activation. PLoS ONE, 2014, 9, e100719.	1.1	72
69	Memory and mood during MDMA intoxication, with and without memantine pretreatment. Neuropharmacology, 2014, 87, 198-205.	2.0	28
70	Methylphenidate reduces functional connectivity of nucleus accumbens in brain reward circuit. Psychopharmacology, 2013, 229, 219-226.	1.5	46
71	Single doses of <scp>THC</scp> and cocaine decrease proficiency of impulse control in heavy cannabis users. British Journal of Pharmacology, 2013, 170, 1410-1420.	2.7	31
72	Inhibition of <scp>MDMA</scp>â€induced increase in cortisol does not prevent acute impairment of verbal memory. British Journal of Pharmacology, 2013, 168, 607-617.	2.7	20

#	Article	IF	Citations
73	Psychomotor Function in Chronic Daily Cannabis Smokers during Sustained Abstinence. PLoS ONE, 2013, 8, e53127.	1.1	69
74	Escitalopram Decreases Cross-Regional Functional Connectivity within the Default-Mode Network. PLoS ONE, 2013, 8, e68355.	1.1	52
75	A placebo-controlled study to assess Standardized Field Sobriety Tests performance during alcohol and cannabis intoxication in heavy cannabis users and accuracy of point of collection testing devices for detecting THC in oral fluid. Psychopharmacology, 2012, 223, 439-446.	1.5	52
76	MDMA (ecstasy) effects on actual driving performance before and after sleep deprivation, as function of dose and concentration in blood and oral fluid. Psychopharmacology, 2012, 222, 367-376.	1.5	22
77	Effects of stimulant drugs on actual and simulated driving: perspectives from four experimental studies conducted as part of the DRUID research consortium. Psychopharmacology, 2012, 222, 413-418.	1.5	15
78	Medicinal Î”⁹â€tetrahydrocannabinol (dronabinol) impairs onâ€theâ€road driving performance of occasional and heavy cannabis users but is not detected in <scp>S</scp>tandard <scp>F</scp>ield <scp>S</scp>obriety <scp>T</scp>ests. Addiction, 2012, 107, 1837-1844.	1.7	91
79	Effects of Acute MDMA Intoxication on Mood and Impulsivity: Role of the 5-HT2 and 5-HT1 Receptors. PLoS ONE, 2012, 7, e40187.	1.1	77
80	A Case-Control Study Estimating Accident Risk for Alcohol, Medicines and Illegal Drugs. PLoS ONE, 2012, 7, e43496.	1.1	69
81	S.23.04 Effects of MDMA on mood and memory. European Neuropsychopharmacology, 2011, 21, S223.	0.3	0
82	Blockade of 5-HT2 Receptor Selectively Prevents MDMA-Induced Verbal Memory Impairment. Neuropsychopharmacology, 2011, 36, 1932-1939.	2.8	40
83	MDMA intoxication and verbal memory performance: a placebo-controlled pharmaco-MRI study. Journal of Psychopharmacology, 2011, 25, 1053-1061.	2.0	15
84	Dose-related effects of MDMA on psychomotor function and mood before, during, and after a night of sleep loss. Psychopharmacology, 2010, 209, 69-76.	1.5	15
85	P.6.c.001 Cortisol levels and MDMA-induced memory impairment. European Neuropsychopharmacology, 2010, 20, S581-S582.	0.3	0
86	Involvement of Inferior Parietal Lobules in Prospective Memory Impairment during Acute MDMA (Ecstasy) Intoxication: An Event-Related fMRI Study. Neuropsychopharmacology, 2009, 34, 1641-1648.	2.8	39
87	Sustained attention and serotonin: a pharmacoâ€fMRI study. Human Psychopharmacology, 2008, 23, 221-230.	0.7	53
88	Memory and mood during the night and in the morning after repeated evening doses of MDMA. Journal of Psychopharmacology, 2008, 22, 895-903.	2.0	20
89	Selective verbal and spatial memory impairment after 5-HT1A and 5-HT2A receptor blockade in healthy volunteers pre-treated with an SSRI. Journal of Psychopharmacology, 2007, 21, 477-485.	2.0	37
90	The role of 5-HT1a and 5-HT2a receptors in attention and motor control: a mechanistic study in healthy volunteers. Psychopharmacology, 2007, 190, 391-400.	1.5	35

#	Article	IF	Citations
91	Acute effects of nocturnal doses of MDMA on measures of impulsivity and psychomotor performance throughout the night. Psychopharmacology, 2007, 192, 111-119.	1.5	34
92	A combined neurophysiological and behavioural study into the stimulating effects of fexofenadine on performance. Journal of Psychopharmacology, 2006, 20, 496-505.	2.0	18
93	Stimulant effects of 3,4-methylenedioxymethamphetamine (MDMA) 75â€ƒmg and methylphenidate 20â€ƒmg on actual driving during intoxication and withdrawal. Addiction, 2006, 101, 1614-1621.	1.7	64
94	Acute dose of MDMA (75Âmg) impairs spatial memory for location but leaves contextual processing of visuospatial information unaffected. Psychopharmacology, 2006, 189, 557-563.	1.5	47
95	MDMA and alcohol effects, combined and alone, on objective and subjective measures of actual driving performance and psychomotor function. Psychopharmacology, 2006, 187, 467-475.	1.5	83
96	Acute Effects of 3,4-Methylenedioxymethamphetamine (MDMA) on Behavioral Measures of Impulsivity: Alone and in Combination with Alcohol. Neuropsychopharmacology, 2006, 31, 1048-1055.	2.8	95
97	Transient memory impairment after acute dose of 75mg 3.4-Methylene-dioxymethamphetamine. Journal of Psychopharmacology, 2005, 19, 633-639.	2.0	76
98	Amphetamine & Methamphetamine: Pharmacokinetics and Pharmacodynamics. , 0, , 131-151.		1
99	Psychedelic-Assisted Psychotherapyâ€”A Systematic Review of Associated Psychological Interventions. Frontiers in Psychology, 0, 13, .	1.1	17
100	Decreases in State and Trait Anxiety Post-psilocybin: A Naturalistic, Observational Study Among Retreat Attendees. Frontiers in Psychiatry, 0, 13, .	1.3	5